Clinical trials: Phase I
Soft Tissue Sarcoma
Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma.
- Trial name
- NCT00742963
- Testing
- TH-302
- Where
- 9 sites in United States
- Volunteers
- 107 people
- Sponsor
- ImmunoGenesis
Human Cancers
Phase I Study of MOv18 IgE
This first in human study of the new therapeutic antibody MOv18 immunoglobulin (Ig) E, which targets a protein called folate receptor alpha (FRa), in patients with advanced cancer seeks to demonstrate the potential for the use of…
- Trial name
- NCT02546921
- Testing
- MOv18 IgE
- Where
- 4 sites in United Kingdom
- Volunteers
- 26 people
- Sponsor
- Cancer Research UK
Metastatic Colorectal Cancer, MSS
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
This is a monocentric, single arm, prospective, open-label trial of a combination treatment consisting of pembrolizumab and maraviroc in previously treated subjects who have refractory microsatellite stable (MSS) metastatic…
- Trial name
- PICCASSO (NCT03274804)
- Testing
- Pembrolizumab, Maraviroc
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg
Infections, Bacterial
To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.
This study is divided in 2 parts. Part 1a is being conducted to evaluate the safety, tolerability, and relative bioavailability of the 2 free base tablet formulations (roller compacted [RC] and high shear wet granulation [HSWG])…
- Trial name
- NCT02853435
- Testing
- Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Recurrent Melanoma, Stage III Melanoma
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
Phase II trial to study the effectiveness of combining imatinib mesylate with bevacizumab in treating patients who have advanced melanoma or other metastatic or unresectable cancer.
- Conditions
- Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00074308
- Testing
- imatinib mesylate, bevacizumab, pharmacological study
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
β-thalassemia Major
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants
This is a non-randomized, open label, multi-site, single-dose, phase 1/2 study in up to 18 participants (including at least 3 adolescents between 12 and 17 years of age, inclusive) with β-thalassemia major.
- Trial name
- NCT01745120
- Testing
- LentiGlobin BB305 Drug Product
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 19 people
- Sponsor
- Genetix Biotherapeutics Inc.
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and…
- Conditions
- Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
- Trial name
- NCT05617885
- Testing
- Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Praful Ravi, MB BCHir, MRCP
Breast Cancer
LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
This single center Phase I dose escalation trial will evaluate the safety, tolerability and efficacy of LBH589 when combined with capecitabine and lapatinib in three parts.
- Trial name
- NCT00632489
- Testing
- LBH589, Capecitabine, Lapatinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SCRI Development Innovations, LLC
Advanced Solid Tumors
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell…
- Trial name
- NCT06024174
- Testing
- BMS-986466, Adagrasib, Cetuximab
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Autologous Dendritic Cell Vaccine in HIV1 Infection
This study aims to look at the safety and tolerability of immunization with dendritic cell vaccine prepared using the patient's own cells and virus.
- Trial name
- NCT00510497
- Testing
- Autologous HIV-1 ApB DC Vaccine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sharon Riddler
Myeloid Malignancy
APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
This clinical trial is a Phase I, open-label, dose-finding and cohort expansion study to determine the safety and preliminary efficacy of APR-246 in combination with venetoclax and azacitidine in patients with myeloid…
- Trial name
- NCT04214860
- Testing
- APR-246, Venetoclax, Azacitidine
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- Aprea Therapeutics
Attention-Deficit Hyperactivity Disorder
Pharmacokinetics of HLD200 in Children and Adolescents With ADHD
This study was designed to assess the pharmacokinetic effects of a single dose of HLD200 (methylphenidate hydrochloride) in children and adolescents with ADHD.
- Trial name
- NCT01907360
- Testing
- HLD200 (methylphenidate hydrochloride)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
Solid Tumor
BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
This was an open-label, multicenter Phase I/IIa dose escalation, safety, pharmacokinetic and pharmacodynamic (PD) study of BNT151 with expansion cohorts in various solid tumor indications.
- Trial name
- NCT04455620
- Testing
- BNT151
- Where
- 6 sites in United States, Spain
- Volunteers
- 49 people
- Sponsor
- BioNTech SE
Chronic Hepatitis D Infection
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the…
- Trial name
- NCT05760300
- Testing
- Bulevirtide (BLV)
- Where
- 9 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Lymphoma, Carcinoma
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer
Background: People with cancer can have a weak immune system as a result of the cancer itself, or from prior treatments. Still, treatments that stimulate the immune system have been shown to be effective against a number of…
- Trial name
- NCT01572493
- Testing
- rh IL-15 (10 DAYS), rh IL-15 (5 DAYS)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
IDH1-mutant Cholangiocarcinoma
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
This is a Phase 1/2 study evaluating the safety, tolerability, and activity of ivosidenib in combination with immunotherapy in participants with nonresectable or metastatic cholangiocarcinoma.
- Trial name
- NCT05921760
- Testing
- Ivosidenib, Nivolumab, Ipilimumab
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Servier Bio-Innovation LLC
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery
This study combines the deoxyribonucleic acid (DNA) methyltransferase inhibitor, 5-azacitidine (5-AZA), with an orally bioavailable histone deacetylase inhibitor, entinostat (SNDX-275), for the adjuvant treatment of patients with…
- Trial name
- NCT01207726
- Testing
- Azacitidine, Entinostat, Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Abdominal Aortic Aneurysm
A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms
This study was a prospective observational study examined the safety of the TriVascular AAA Stent-Graft System in the elective treatment of patients with abdominal aortic aneurysms.
- Trial name
- AAA IDE (NCT00646048)
- Testing
- TriVascular Stent-Graft System
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- Boston Scientific Corporation
Lung Cancer
Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn if escalated/accelerated proton radiotherapy can improve the control of Non-Small Cell Lung Cancer (NSCLC) and decrease side effects.
- Trial name
- NCT00495040
- Testing
- Proton Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Complex Partial Seizures
Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients
This is an open-label, phase 4 study to examine the safety and efficacy of vigabatrin (Sabril) in Tuberous Sclerosis patients, a subset of the larger refractory complex partial epilepsy population for which the drug is approved.
- Trial name
- STARS (NCT01266291)
- Testing
- vigabatrin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Pennsylvania
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.